Literature DB >> 19901108

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Hideki Makishima1, Heather Cazzolli, Hadrian Szpurka, Andrew Dunbar, Ramon Tiu, Jungwon Huh, Hideki Muramatsu, Christine O'Keefe, Eric Hsi, Ronald L Paquette, Seiji Kojima, Alan F List, Mikkael A Sekeres, Michael A McDevitt, Jaroslaw P Maciejewski.   

Abstract

PURPOSE: Acquired somatic uniparental disomy (UPD) is commonly observed in myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), or secondary acute myelogenous leukemia (sAML) and may point toward genes harboring mutations. Recurrent UPD11q led to identification of homozygous mutations in c-Cbl, an E3 ubiquitin ligase involved in attenuation of proliferative signals transduced by activated receptor tyrosine kinases. We examined the role and frequency of Cbl gene family mutations in MPN and related conditions.
METHODS: We applied high-density SNP-A karyotyping to identify loss of heterozygosity of 11q in 442 patients with MDS, MDS/MPN, MPN, sAML evolved from these conditions, and primary AML. We sequenced c-Cbl, Cbl-b, and Cbl-c in patients with or without corresponding UPD or deletions and correlated mutational status with clinical features and outcomes.
RESULTS: We identified c-Cbl mutations in 5% and 9% of patients with chronic myelomonocytic leukemia (CMML) and sAML, and also in CML blast crisis and juvenile myelomonocytic leukemia (JMML). Most mutations were homozygous and affected c-Cbl; mutations in Cbl-b were also found in patients with similar clinical features. Patients with Cbl family mutations showed poor prognosis, with a median survival of 5 months. Pathomorphologic features included monocytosis, monocytoid blasts, aberrant expression of phosphoSTAT5, and c-kit overexpression. Serial studies showed acquisition of c-Cbl mutations during malignant evolution.
CONCLUSION: Mutations in the Cbl family RING finger domain or linker sequence constitute important pathogenic lesions associated with not only preleukemic CMML, JMML, and other MPN, but also progression to AML, suggesting that impairment of degradation of activated tyrosine kinases constitutes an important cancer mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901108      PMCID: PMC3040009          DOI: 10.1200/JCO.2009.23.7503

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  29 in total

1.  Detection of large-scale variation in the human genome.

Authors:  A John Iafrate; Lars Feuk; Miguel N Rivera; Marc L Listewnik; Patricia K Donahoe; Ying Qi; Stephen W Scherer; Charles Lee
Journal:  Nat Genet       Date:  2004-08-01       Impact factor: 38.330

2.  The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl was generated by a large truncation encompassing a proline-rich domain and a leucine zipper-like motif.

Authors:  T J Blake; M Shapiro; H C Morse; W Y Langdon
Journal:  Oncogene       Date:  1991-04       Impact factor: 9.867

Review 3.  The Cbl interactome and its functions.

Authors:  Mirko H H Schmidt; Ivan Dikic
Journal:  Nat Rev Mol Cell Biol       Date:  2005-12       Impact factor: 94.444

4.  Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

Authors:  Stefan Fröhling; Daniel B Lipka; Sabine Kayser; Claudia Scholl; Richard F Schlenk; Hartmut Döhner; D Gary Gilliland; Ross L Levine; Konstanze Döhner
Journal:  Blood       Date:  2006-02-01       Impact factor: 22.113

5.  Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias.

Authors:  Saman Abbas; Gabriëlle Rotmans; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2008-08-12       Impact factor: 9.941

6.  UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.

Authors:  H Szpurka; L P Gondek; S R Mohan; E D Hsi; K S Theil; J P Maciejewski
Journal:  Leukemia       Date:  2008-09-25       Impact factor: 11.528

7.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

8.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

9.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

10.  Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice.

Authors:  M A Murphy; R G Schnall; D J Venter; L Barnett; I Bertoncello; C B Thien; W Y Langdon; D D Bowtell
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

View more
  86 in total

Review 1.  Pathogenesis and consequences of uniparental disomy in cancer.

Authors:  Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Clin Cancer Res       Date:  2011-04-25       Impact factor: 12.531

2.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

Review 3.  Molecular biology of myelodysplastic syndromes.

Authors:  Alan H Shih; Ross L Levine
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 4.  Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.

Authors:  Stephen C Kales; Philip E Ryan; Marion M Nau; Stanley Lipkowitz
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

5.  Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.

Authors:  Sarah Abu Kar; Anna Jankowska; Hideki Makishima; Valeria Visconte; Andres Jerez; Yuka Sugimoto; Hideki Muramatsu; Fabiola Traina; Manuel Afable; Kathryn Guinta; Ramon V Tiu; Bartlomiej Przychodzen; Hirotoshi Sakaguchi; Seiji Kojima; Mikkael A Sekeres; Alan F List; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

6.  Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins.

Authors:  Scott Nadeau; Wei An; Nick Palermo; Dan Feng; Gulzar Ahmad; Lin Dong; Gloria E O Borgstahl; Amarnath Natarajan; Mayumi Naramura; Vimla Band; Hamid Band
Journal:  Biochem Anal Biochem       Date:  2012-07-30

Review 7.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

8.  Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.

Authors:  Ramon V Tiu; Lukasz P Gondek; Christine L O'Keefe; Paul Elson; Jungwon Huh; Azim Mohamedali; Austin Kulasekararaj; Anjali S Advani; Ronald Paquette; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Ghulam J Mufti; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-02-01       Impact factor: 22.113

9.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

10.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.